If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"false","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"","arm_groups":[{"arm_group_label":"TIVICAY tablets","arm_group_description":"Patients with HIV infection to whom TIVICAY tablets are administered (prescribed).","arm_type":""}],"assignment":"","brief_summary":"This post-marketing surveillance (PMS) is conducted to collect safety and efficacy data among subjects with allergic rhinitis who are treated with dolutegravir tablets for the first time. (TIVICAY is a trademark of the GlaxoSmithKline group of companies.)","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Drug Use Investigation for Tivicay® tablet (HRD Cooperative Investigation)","conditions":[{"DisplayValue":"Immune, Inflammatory & Infections - Other","DisplayValue_OneLinkTx":"","InternalValue":"CON_IMMUNE_OTHER","LookupValue":"Virus Diseases","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 20:59:50","criteria":"Inclusion Criteria: -Patients with HIV infection Exclusion Criteria: - None","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"","display_phase_internal":"","display_status":"Ongoing","display_status_internal":"RECSTATUS_O_ONGOING","endpoint":"","enrollment":"9999","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"None","id":"f5cd4712-64f6-5df9-b16d-8a486893eec4","internal":{"content":null,"contentDigest":"8439cee30df0078cc9951434d24070a0","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: -Patients with HIV infection Exclusion Criteria: - None","interventions":[{"arm_group_label":"TIVICAY tablets","intervention_description":"1 tablet/dose (dolutegravir 50mg), once daily","intervention_name":"TIVICAY tablets","intervention_type":"drug"}],"interventional_subtype":"","is_fda_regulated":true,"is_high_value":false,"is_ind_study":false,"keywords":[],"last_follow_up_date":"03/23/2024 00:00:00","links":[],"locations":[],"masking":"","maximum_age_raw":"","maximum_age":null,"minimum_age":null,"minimum_age_raw":"","modified_date":"10/01/2018 22:37:28","number_of_arms":"0","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"0","observational_study_design":"Other","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":"Other"},"official_title":"Drug Use Investigation for Tivicay® tablet (HRD Cooperative Investigation)","org_study_id":"201933","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Active, not recruiting - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":["Japan: Pharmaceuticals and Medical Devices Agency"]},"phase":"","primary_compl_date":"03/23/2024 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"The incidence of adverse drug reactions","outcome_time_frame":"5years","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GSK"]},"start_date":"09/03/2014 00:00:00","study_type":"Observational","therapeutic_area":"","citations":[],"is_section_801":false}},"pageContext":{"studyId":"201933"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}